$120.00
Tesamorelin
GHRH analog that specifically reduces visceral fat, improves lipid profiles and body composition, while supporting cognitive function and metabolic health.
- FDA-approved for reducing visceral adiposity in HIV-associated lipodystrophy
- Investigated for potential metabolic and anti-aging applications
- Stimulates GH/IGF-1 release
- API per Vial: 10 mg
- Dose: 1-2mg
- Frequency: Once daily
- Route: SQ
38 in stock
Description
GHRH Analog
What is Tesamorelin?
Tesamorelin is a synthetic peptide medication used for specific medical purposes. It is designed to stimulate the production of growth hormone-releasing hormone (GHRH) in the body.
How does Tesamorelin work in the body?
Tesamorelin works by enhancing the secretion of growth hormone (GH) from the pituitary gland. It does this by mimicking the action of natural GHRH, which stimulates the release of GH.
Primary Benefits:
- Improved Fat Metabolism & Body Composition: Reduces visceral adipose tissue (VAT)
- Enhanced Cognitive Function: May have neuroprotective effects and improve cognitive function
- Support for Skin & Muscle Health: Promotes synthesis of growth hormone for healthier skin and muscle
- Reduces visceral fat specifically
- Improves lipid profiles
- Enhanced body composition
The Science Behind Tesamorelin
The science behind Tesamorelin lies in its ability to modulate the production of growth hormone in the body. At its core, Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), a naturally occurring peptide that stimulates the pituitary gland to release growth hormone (GH). By mimicking GHRH, Tesamorelin effectively amplifies the body’s own GH secretion, which plays a pivotal role in various physiological processes, including growth, metabolism, and tissue repair. This mechanism of action is particularly relevant in the context of HIV-associated lipodystrophy, where Tesamorelin’s ability to promote the redistribution of body fat and improve metabolic parameters has been clinically demonstrated.
Best for: Individuals focused on fat loss and metabolic health improvement.
Frequently Asked Questions
Are there any potential side effects associated with Tesamorelin?
Common side effects of Tesamorelin may include joint pain, injection site reactions, and muscle pain. It’s important to discuss potential side effects with a healthcare provider.
How is Tesamorelin administered to patients?
Tesamorelin is typically administered by subcutaneous injection, usually on a daily basis, as directed by a healthcare professional.
What is the typical treatment duration for Tesamorelin therapy?
The treatment duration with Tesamorelin can vary depending on individual patient needs and the condition being treated. It is typically used for several months to achieve desired outcomes.
What ongoing research or developments are there in the field of Tesamorelin therapy?
Ongoing research is exploring potential new applications for Tesamorelin in areas such as muscle wasting disorders and metabolic conditions. Keep an eye on emerging studies and clinical trials for the latest developments.
Overview
Tesamorelin GHRH Analog
Category: Growth Hormone Optimization
How It Works
Stimulates growth hormone release to reduce visceral adipose tissue
Benefits
- FDA-approved for reducing visceral adiposity in HIV-associated lipodystrophy
- Investigated for potential metabolic and anti-aging applications
- Stimulates GH/IGF-1 release
- Supports body composition improvements
Best For
- Visceral fat reduction
- Body composition
- Metabolic health
Recommended Protocol
| API per Vial | 10 mg |
|---|---|
| Dosage | 1-2mg |
| Frequency | Once daily |
| Administration | SQ |
| Cycle Length | 3-6 months |
| Break Period | 1-2 months |
| Half-Life | ~26 minutes |
Safety Information
Experience Level: Intermediate
Medical Supervision: Not Required
Contraindications
- Active cancer
- Pregnancy
- Breastfeeding
- Pituitary disorders
Recommended Monitoring
- Monitor visceral fat
- Track IGF-1 levels
- Watch for injection site reactions
Regulatory Status: FDA-approved for visceral fat reduction in HIV lipodystrophy (Egrifta)
Additional Notes
IGF-1 monitoring recommended for long-term use. Specifically targets visceral fat.

